228850.Kq
The company designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic and therapeutic devices for healthcare applications.
Business. The company designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic and therapeutic devices for healthcare applications.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic and therapeutic devices for healthcare applications.
The company maintains a strong liquidity position, with a current ratio of 14.95, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 47.5 billion KRW, which supports operational flexibility and short-term obligations. The price-to-book ratio of 0.46 suggests that the company is trading at a discount relative to its book value, potentially indicating undervaluation or underlying financial challenges.
Profitability metrics reveal a challenging financial position. The company reported a net loss of 5.3 billion KRW and an operating loss of 9.2 billion KRW, with a negative return on equity of -2.23% and a return on assets of -2.02%. These figures are below the industry median for profitability, indicating underperformance relative to peers in the Advanced Medical Equipment & Technology industry.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, which is sensitive to regulatory and reimbursement changes.
Looking ahead, the company is expected to face continued financial pressure. Analysts project a mean price target of 7,000 KRW, slightly above the current market price of 6,970 KRW. However, the company's free cash flow is negative at -4.5 billion KRW, and capital expenditures are trending downward, suggesting a potential slowdown in investment and growth.
Risk factors include the company's negative net income and operating income, which could impact its ability to sustain operations without external financing. The dilution risk is currently low, with no immediate filing-based flags detected, and the debt-to-equity ratio of 0.02 indicates a conservative capital structure.
Recent events include a single "Buy" recommendation from analysts, with no "Strong Buy" or "Hold" ratings. The company has not disclosed any major recent filings or transcripts that would suggest significant operational or strategic changes.
- The company is trading at a significant discount to book value, with a price-to-book ratio of 0.46.
- Profitability is negative, with a return on equity of -2.23% and a return on assets of -2.02%.
- The company has a strong liquidity position, with a current ratio of 14.95 and 47.5 billion KRW in cash and equivalents.
- Analysts have issued a single "Buy" recommendation, with no "Strong Buy" or "Hold" ratings.
- The company's financial performance is below industry medians, indicating underperformance relative to peers.
- The company has no immediate liquidity or dilution risks, but its negative free cash flow and operating losses may require future financing.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 356,00 |
| Revenue | —no estimate | —no estimate | 114,4B KRW |
| Operating income | —no estimate | —no estimate | 4,4B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 228850.KQ Market data — financials · 2026-05-26
- Rayence Co Ltd Market data — analyst estimates · 2026-05-26